GOLDSMITH MARK A sold $2.8M of RVMD

Brookline Capital Markets initiated coverage on Revolution Medicines (NASDAQ:RVMD) with a buy rating and a $318 price target. The stock is up 367% over the past year. Brookline estimates revenue growing from $151M in 2026 to $59.5B in 2033, with positive cash flow expected in 2027. The company recently launched Rasonque for pancreatic cancer, with FDA approval based on improved survival rates.

Revolution Medicines (RVMD) received FDA Breakthrough Therapy Designation for its cancer treatment, boosting its profile. The stock has surged 152.92% year-to-date, with analysts valuing it at $251.21, above its current $199.86. The company's pipeline includes eight Phase III trials, with potential long-term revenue growth if successful.

Revolution Medicines (RVMD) received FDA breakthrough designation for RASONQUE, a pancreatic cancer drug. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX has risen 60% in a year, providing diversified risk.

Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.

Revolution Medicines (RVMD) rose 4.8% after Goldman Sachs initiated coverage with a Buy rating, citing confidence in its oncology platform. The FDA granted Breakthrough Therapy Designation to RASONQUE for pancreatic cancer, reinforcing regulatory momentum. Recent U.S. approval of RASONQUE also supports the stock's transition to a commercial-stage company.

Revolution Medicines (RVMD) shares rose after Goldman Sachs initiated coverage with a Buy rating and a $267 price target, citing its drug pipeline and deal activity. The company's cancer drug and pipeline offer growth potential, but risks include cash burn and regulatory uncertainties.